|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Embolism, pulmonary |
|
Myocardial infarction |
|
Occlusion, intravenous catheter |
|
Thrombosis, coronary artery |
| |
|
|
SIDE EFFECTS:
|
|
anaphylactoid reactions |
|
angioedema |
|
back pain |
|
bleeding |
|
chills |
|
cholesterol microembolization |
|
cyanosis |
|
dyspnea |
|
ecchymosis |
|
fever |
|
GI bleeding |
|
hematoma |
|
hematuria |
|
hemoptysis |
|
hypertension |
|
hypotension |
|
hypoxia |
|
infection |
|
intracranial bleeding |
|
laryngeal edema |
|
nausea/vomiting |
|
premature ventricular contractions (PVCs) |
|
pruritus |
|
purpura |
|
rash (unspecified) |
|
sinus bradycardia |
|
sinus tachycardia |
|
stroke |
|
urticaria |
|
ventricular tachycardia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
atrial fibrillation |
|
atrial flutter |
|
breast-feeding |
|
cardiac arrhythmias |
|
cardiac disease |
|
diabetic retinopathy |
|
elderly |
|
endocarditis |
|
GI bleeding |
|
hepatic disease |
|
infection |
|
intramuscular injections |
|
mitral stenosis |
|
obstetric delivery |
|
organ biopsy |
|
peptic ulcer disease |
|
pericarditis |
|
pregnancy |
|
renal disease |
|
renal failure |
|
surgery |
|
thrombophlebitis |
|
trauma |
|
anticoagulant therapy |
|
|
ADULT DOSE:
|
|
Thrombosis, coronary arterial, acute-
Intra-arterial (via a coronary artery catheter), 6000 IU (4 mL of a solution containing approximately 1500 IU per mL) per minute .
Note: The average total dose of urokinase required for lysis of coronary artery thrombi is 500,000 IU .
Urokinase administration should be continued until the artery is maximally opened, usually fifteen to thirty minutes after initial opening .
The medication has been administered for periods of up to two hours.
Periodic coronary angiography, at approximately fifteen-minute intervals, is recommended during the infusion with urokinase .
Thromboembolism, pulmonary, acute-
Intravenous, 4400 IU per kg of body weight initially over a ten-minute period, followed by 4400 IU per kg of body weight per hour for approximately twelve hours .
Note: Manufacturer"s product information should be consulted for recommendations concerning the rate of infusion, based on recommended dilution volume of the product .
Heparin should be discontinued during the intravenous administration of urokinase .
Catheter, intravenous, clearance-
After the intravenous tubing has been disconnected and catheter occlusion confirmed, the catheter should be filled with a solution containing 5000 IU per mL of urokinase . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|